New York, NY, United States
New York, NY, United States
SEARCH FILTERS
Time filter
Source Type

The present invention relates to compositions that include one or more control molecules known as artificial reference sequences and methods of using these control molecules for estimating rare nucleic acid sequence variants from low copy numbers in ultra-deep sequencing.


The invention provides novel methods and kits for isolating nucleic acids from biological samples, including cell-free DNA and/or cell-free DNA and nucleic acids including at least RNA from microvesicles, and for extracting nucleic acids from the microvesicles and/or from the biological samples.


Patent
Exosome Diagnostics | Date: 2017-08-09

In order to address an inability to separate portions of a sample and/or substance, in some embodiments, methods and apparatuses for separating components and/or portions of a sample are provided. For example, a sample collection container may comprise two areas within the container, one which is configured to contain a first volume of the sample, and one which is configured to contain a second volume of the sample. A float device may be configured to seal the portion of the container collecting the first volume from the portion of the container collecting the second volume, after the former portion of the container has been filled. The sample collection container may further comprise a top cap configured to further seal the two portions of the container, and to prevent leakage and/or spilling of the sample from the sample collection container.


A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA.


The present invention discloses methods for diagnosing or prognosing a disease or medical condition in a subject by detecting the presence or absence of BRAF mutant nucleic acids from nucleic acids extracted from microvesicles from a biological sample. The present invention also discloses methods for assessing the responsiveness or determining a treatment regimen for a subject in need thereof by detecting the presence or absence of BRAF mutant nucleic acids from nucleic acids extracted from microvesicles from a biological sample. Methods for isolating microvesicles and extracting DNA and/or RNA from the microvesicles are also described.


Patent
Exosome Diagnostics | Date: 2014-01-03

The invention provides novel methods for isolating microvesicles from a biological sample and for extracting nucleic acids from the microvesicles.


Patent
Exosome Diagnostics | Date: 2016-04-26

Methods for extracting high quality nucleic acids from a heterogenous collection of nucleic acid-containing materials from a biological sample are disclosed. The heterogenous collection of nucleic-acid containing materials may contain cells or microvesicles, or both. The extractions obtained by the methods described herein are characterized by high yield and high integrity, making the extracted nucleic acids useful for various applications in which high quality nucleic acid extractions are preferred, e.g., a diagnosis, prognosis, or therapy evaluation for a medical condition.


The present invention relates generally to the field of biomarker analysis, particularly determining gene expression signatures from urine samples. The disclosure provides compositions, kits and methods for diagnosing a prostate disorder such as prostate cancer in a male subject.


Patent
Exosome Diagnostics | Date: 2014-10-07

A method for detecting biomarkers of prostate cancer or other medical condition of the prostate based on the use of microvesicles obtained from urine samples, and the nucleic acids present in the microvesicles. The method disclosed herein are advantageous in that they may be used to support diagnosis, prognosis, monitoring, or therapy selection in lieu of or in conjunction with traditional biopsy-based diagnostics and do not require a digital rectal examination or prostate massage prior to urine sample collection.


Patent
Exosome Diagnostics | Date: 2014-02-14

The present invention features a novel EGFR variant, EGFRvVI, and methods for detecting the novel EGFR variant. The novel EGFR variant is preferentially expressed in some cancers. Methods for detecting EGFRvVI may aid in the diagnosis, prognosis, and therapeutic assessment of a subject.

Loading Exosome Diagnostics collaborators
Loading Exosome Diagnostics collaborators